Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies

Inclusion Criteria:

1. Written informed consent must be obtained before participating in the study

2. Diagnosis of RMS per McDonald Criteria (2017) (Thompson, Banwell et al. 2018)

3. Prior treatment with EU approved DMT for MS other than ofatumumab

4. Decision for treatment initiation of ofatumumab (Kesimpta®) prior to studyparticipation and planned initiation of ofatumumab after respective wash-out periodof prior DMT (if applicable) or performed initiation of ofatumumab within the last 14 days

5. Ofatumumab treatment in line with the German label

Exclusion Criteria:

1. Use of investigational drugs during the study, OR within 3 months before ofatumumabinitiation, OR within 5 half-lives of investigational drug before ofatumumabinitiation, OR until the expected pharmacodynamic effect has returned to baseline,whichever is longer

2. Subjects who are not able to provide consent due to incapable judgement

3. Simultaneous participation in any investigational trial or simultaneousparticipation in another Novartis-sponsored non-interventional study with ofatumumab